Anti-GD2 (Naxitamab), Humanized Antibody

Anti-GD2 (Naxitamab), Humanized Antibodyis available at Gentaur for Next week Delivery.

Description: The research-grade biosimilar is a recombinant humanized IgG1 monoclonal antibody that targets ganglioside GD2. GD2 is a disialoganglioside that is expressed in neuroblastomas, melanomas, bone and soft tissue sarcomas, brain tumors, and small cell lung cancer. Although its function is not clearly understood, it may be playing an essential role in attaching tumor cells to extracellular matrix proteins. Due to its tumor-specific expression, GD2 serves as a suitable target for tumor-specific antibody therapy. The antibody binds to GD2 and causes cell death via complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). The original monoclonal antibody is FDA approved to treat adult and pediatric patients suffering from relapsed/refractory neuroblastoma.

Immunogen Sequence:Human GD2

Target Alternative Name:GD2 Ganglioside, GD2, CAS 65988-71-8

Species Reactivities:Human

Tag Line:The biosimilar is a humanized monoclonal antibody that targets ganglioside GD2

Formulation:In PBS, pH 7.5

Purification: Protein A purified

Application:/

Positive Control:/

Application And Usages:/

Handling:The antibody solution should be gently mixed before use.